Laurion Capital Management LP Apellis Pharmaceuticals, Inc. Transaction History

Laurion Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $11.4 Million - $13.9 Million	148,590 Added 39.69%	522,929 $47.6 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $17.4 Million - $25.1 Million	374,339 New	374,339 $24.7 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $771,540 - $1.3 Million	-22,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $780,120 - $1.19 Million	22,000 New	22,000 $1.12 Million
Q1 2018 May 14, 2018	SELL	$14.01 - $26.02 $700,500 - $1.3 Million	-50,000 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$12.71 - $21.7 $635,500 - $1.09 Million	50,000	50,000 $1.09 Million

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.